Elevance Health's Net Income Declines 24.2% in Q2 2025

Elevance Health, Inc. reported its second quarter 2025 financial results, with operating revenue reaching $49.4 billion, marking a 14.3% increase from the prior year quarter. Despite the revenue growth, net income for the quarter stood at $1.744 billion, representing a 24.2% decrease compared to $2.301 billion in Q2 2024. Diluted EPS for the quarter was $7.72. The reported operating revenue of $49.4 billion exceeded the analyst estimate of $48.257 billion, while the diluted EPS of $7.72 missed the analyst estimate of $9.20.

Key Business Drivers

The company's operating revenue growth was primarily fueled by higher premium yields in its Health Benefits segment, recently closed acquisitions, and an increase in Medicare Advantage membership. This growth was partially offset by membership attrition within the Medicaid business. The Health Benefits segment's operating revenue increased by 12% to $41.6 billion, though its operating gain decreased to $1.6 billion due to higher medical cost trends in the Medicaid business and ACA health plans.

Carelon segment revenue surged by 36% to $18.1 billion, largely attributable to recent acquisitions in home health and pharmacy services, growth in CarelonRx product revenue, and the scaling of innovative risk-based capabilities in Carelon Services. Carelon's operating gain also saw a substantial increase of 33%, reaching $0.9 billion, driven by improved Carelon Health performance and higher CarelonRx product revenue.

Management Outlook

Gail K. Boudreaux, President and Chief Executive Officer, noted the company's progress in enhancing efficiency across the healthcare system despite ongoing industry-wide challenges from elevated cost trends in ACA and Medicaid. The company has revised its fiscal year 2025 adjusted diluted EPS guidance to approximately $30.00, reflecting these trends and slower rate alignment in Medicaid. Management remains confident in achieving at least 12% average annual growth in adjusted diluted EPS over time, supported by the embedded earnings power of its diversified Health Benefits and Carelon businesses.